Evaluation of vancomycin individualized model-based dosing approach in neonates.


Journal

Pediatrics and neonatology
ISSN: 2212-1692
Titre abrégé: Pediatr Neonatol
Pays: Singapore
ID NLM: 101484755

Informations de publication

Date de publication:
05 2023
Historique:
received: 05 08 2022
revised: 18 09 2022
accepted: 06 10 2022
medline: 16 5 2023
pubmed: 30 12 2022
entrez: 29 12 2022
Statut: ppublish

Résumé

Vancomycin is commonly used to treat methicillin-resistant staphylococcal infections in neonates. Consensus on its ideal dosing in neonates has not been achieved. Model-based dosing recently has evolved as an important tool to optimize vancomycin initial dosing. The aim of this is to evaluate a population pharmacokinetic model-based approach in achieving the vancomycin therapeutic target of an AUC An Excel calculator was developed using a previously published population pharmacokinetic model in neonates. It was evaluated using retrospectively retrieved data. For each patient, the initial empiric dose was calculated using the proposed Excel model and the most widely used neonatal dosing references. The probability of achieving the target AUC This analysis included 225 neonates. The probability of achieving the target AUC These innovative personalized dosing calculators are promising to improve vancomycin initial dosing in neonates and are easily applicable in routine practices.

Sections du résumé

BACKGROUND
Vancomycin is commonly used to treat methicillin-resistant staphylococcal infections in neonates. Consensus on its ideal dosing in neonates has not been achieved. Model-based dosing recently has evolved as an important tool to optimize vancomycin initial dosing. The aim of this is to evaluate a population pharmacokinetic model-based approach in achieving the vancomycin therapeutic target of an AUC
METHODS
An Excel calculator was developed using a previously published population pharmacokinetic model in neonates. It was evaluated using retrospectively retrieved data. For each patient, the initial empiric dose was calculated using the proposed Excel model and the most widely used neonatal dosing references. The probability of achieving the target AUC
RESULTS
This analysis included 225 neonates. The probability of achieving the target AUC
CONCLUSION
These innovative personalized dosing calculators are promising to improve vancomycin initial dosing in neonates and are easily applicable in routine practices.

Identifiants

pubmed: 36581523
pii: S1875-9572(22)00258-3
doi: 10.1016/j.pedneo.2022.10.006
pii:
doi:

Substances chimiques

Vancomycin 6Q205EH1VU
Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

327-334

Informations de copyright

Copyright © 2022 Taiwan Pediatric Association. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Manal Abouelkheir, Abdullah Almohaizeie, Abdulrahman Almutairi, Sara Almuhisen, Saeed Alqahtani and Abdullah Alsultan declare that they have no conflicts of interest.

Auteurs

Manal Abouelkheir (M)

Department of Clinical Pharmacy, College of Pharmacy, Misr International University, Cairo, Egypt.

Abdullah Almohaizeie (A)

Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Abdulrahman Almutairi (A)

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; Department of Pharmaceutical Care, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Sara Almuhisen (S)

Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia.

Saeed Alqahtani (S)

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Abdullah Alsultan (A)

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. Electronic address: absultan@ksu.edu.sa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH